Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
In: Epilepsia Open, Jg. 9 (2024), Heft 2, S. 689-703
Online
academicJournal
Zugriff:
Abstract Objectives Stiripentol, fenfluramine, and cannabidiol are licensed add‐on therapies to treat seizures in Dravet Syndrome (DS). There are no direct or indirect comparisons assessing their full licensed dose regimens, across different jurisdictions, as first‐line add‐on therapies in DS. Methods We conducted a systematic review and frequentist network meta‐analysis (NMA) of randomized controlled trial (RCT) data for licensed add‐on DS therapies. We compared the proportions of patients experiencing: reductions from baseline in monthly convulsive seizure frequency (MCSF) of ≥50% (clinically meaningful), ≥75% (profound), and 100% (seizure‐free); serious adverse events (SAEs); discontinuations due to AEs. Results We identified relevant data from two placebo‐controlled RCTs for each drug. Stiripentol 50 mg/kg/day and fenfluramine 0.7 mg/kg/day had similar efficacy in achieving ≥50% (clinically meaningful) and ≥75% (profound) reductions from baseline in MCSF (absolute risk difference [RD] for stiripentol versus fenfluramine 1% [95% confidence interval: −20% to 22%; p = 0.93] and 6% [−15% to 27%; p = 0.59], respectively), and both were statistically superior (p
Titel: |
Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first‐line add‐on therapies for seizures in Dravet syndrome: A network meta‐analysis
|
---|---|
Autor/in / Beteiligte Person: | Guerrini, Renzo ; Chiron, Catherine ; Vandame, Delphine ; Linley, Warren ; Toward, Toby |
Link: | |
Zeitschrift: | Epilepsia Open, Jg. 9 (2024), Heft 2, S. 689-703 |
Veröffentlichung: | Wiley, 2024 |
Medientyp: | academicJournal |
ISSN: | 2470-9239 (print) |
DOI: | 10.1002/epi4.12923 |
Schlagwort: |
|
Sonstiges: |
|